entertainment -WSS

entertainment

author：focus 2025-10-01 21:36:53 - browse：4766

FDA's Peter Marks talks with STAT's Adam Feuerstein — Peter Marks, the FDA's top regulator of gene therapies (right), speaks with STAT's Adam Feuerstein in San Francisco. Sarah Gonzalez/Peopletography for STAT

SAN FRANCISCO — Peter Marks, the Food and Drug Administration’s top regulator of gene therapies, seems very comfortable with granting some form of full approval to Elevidys, the Sarepta Therapeutics gene therapy for Duchenne muscular dystrophy, based on his comments to me on Monday night during our “fireside chat” at a STAT event.

To be clear, Marks declined to comment specifically about the ongoing FDA review of Elevidys. I tried. However, Marks described a “hypothetical case” in the context of my Sarepta questions that clearly suggested the failure of an Elevidys confirmatory study in October didn’t bother him all that much.

“Hypothetically, if you had a product that used an aggregate scale and all of the components of that aggregate scale looked pretty good, or nearly all of them look pretty good, but the aggregate, for various reasons, didn’t come out perfectly. We approved products based on that,” Marks told me.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Software glitch causes Tandem insulin pump to shutdown, FDA warns

hotspot

WSS

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Readout Newsletter: Eli Lilly, AstraZeneca, Bristol Meyers Squibb

Biogen joins immunology wave with $1.15 billion acquisition of HI

CDC wastewater surveillance dashboard to track bird flu hotspots

Alcohol isn't healthy after all. Will new dietary guidelines reflect that?

Eyeing GLP

hotspot

entertainment

leisure time

United colonoscopy coverage change 'may cost lives,' doctors say

Elevance, private equity launch primary care company

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Steward Health Care files for bankruptcy

United colonoscopy coverage change 'may cost lives,' doctors say

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

Tori Bowie and the unacceptable rates of Black maternal death

How to improve immunocompromised access to mAb treatments

After affirmative action ruling, medical educators look to 'holistic review'

Telehealth startups turn to complex chronic diseases

hotspot

Making the case for fair compensation in clinical trials

Brain worms: The science behind RFK Jr.'s parasitic infection

Cytokinetics sells Royalty Pharma a share of its heart drug for up to $575M

Readout LOUD podcast: What to know about H5N1 bird flu

Readout LOUD podcast: brain research, obesity drug sales, Novartis

Cytokinetics CEO Robert Blum is on my Worst CEO shortlist again

hotspot

knowledge

knowledge

knowledge